Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Advances in Novel Immunotherapeutics

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9
Introduction
Kunle Odunsi
Roswell Park Cancer Inst., Buffalo, NY, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy
Suresh S Ramalingam
Winship Cancer Institute of Emory University, Atlanta, GA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
Prasad S Adusumilli
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
Genomic analyses and immunotherapy in advanced melanoma
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
Fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 therapy in refractory metastatic melanoma patients - preliminary results from a phase I clinical trial (NCT03353402)
Erez N Baruch
The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
Results of a Phase Ib trial of an autologous cell vaccine for newly diagnosed glioblastoma
David W Andrews
Thomas Jefferson University, Philadelphia, PA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort
Sandip Pravin Patel
UCSD Moores Cancer Center, La Jolla, CA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
A Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer
Hatem Soliman
Moffitt Cancer Center, Tampa, FL, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study
Marina C Garassino
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9